Recent Updates
Recently added Catalysts
ENTA Positive Sentiment

Zelicapavir (EDP-938) Antiviral Treatment is Associated with Shortened Duration of RSV Symptoms in a Randomized, Double-Blind, Placebo-Controlled, Clinical Trial in Children 28 Days to 36 Months of Age

Monday, October 20, 2025 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The clinical trial of Zelicapavir (EDP-938) demonstrated a reduction in the duration of RSV symptoms in children aged 28 days to 36 months. This randomized, double-blind, placebo-controlled study indicates a positive outcome for the antiviral treatment, suggesting its potential as an effective option for managing RSV in young patients.
Price reaction · baseline $11.01 (2025-10-17 close) · hit pre-market · 2 other ENTA headline(s) in the window, move may be shared
day 0 close
+1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Zelicapavir shows promise in reducing RSV symptoms in young children.
  • The study was well-structured with a randomized, double-blind, placebo-controlled design.
  • Potential for significant impact on pediatric RSV treatment.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~63 mo
Minimal dilution risk
Lead asset
EDP-235
Phase 2 · COVID-19

Full Press Release Details

• About About Us Management Team Board of Directors Timeline
• Pipeline Overview Hepatitis C Virus Respiratory Syncytial Virus SARS-CoV-2 Immunology KIT Inhibition STAT6 Inhibition MRGPRX2
• Science Overview Publications
• Patients Overview Clinical Trials Expanded Access Policy Resources
• Careers Join Us Culture Core Values Testimonials Benefits
• Collaborations Partnering
• Investors Overview Press Releases Events & Presentations Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage Financials Quartlery Results Annual Reports SEC Filings Corporate Responsibility Overview Environmental Social Governance Investor Resources Investor FAQs RSS Feed 2026 Annual Meeting Email Alerts
• Contact Us
• About Us
• Management Team
• Board of Directors
• Timeline
• Overview
• Hepatitis C Virus
• Respiratory Syncytial Virus
• SARS-CoV-2
• Immunology KIT Inhibition STAT6 Inhibition MRGPRX2
• KIT Inhibition
• STAT6 Inhibition
• MRGPRX2
• Overview
• Publications
• Overview
• Clinical Trials
• Expanded Access Policy
• Resources
• Join Us
• Culture
• Core Values
• Testimonials
• Benefits
• Partnering
• Overview
• Press Releases
• Events & Presentations
• Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage
• Financials Quartlery Results Annual Reports SEC Filings
• Corporate Responsibility Overview Environmental Social Governance
• Investor Resources Investor FAQs RSS Feed
• 2026 Annual Meeting
• Email Alerts
• Stock Quote & Chart
• Historic Price Lookup
• Investment Calculator
• Analyst Coverage
• Quartlery Results
• Annual Reports
• SEC Filings
• Overview
• Environmental
• Social
• Governance
• Investor FAQs
• RSS Feed
• Print Page Print Page
• Email Alerts Email Alerts
• RSS Feeds RSS Feeds
• Contact IR Contact IR

Frequently Asked Questions

What is Zelicapavir (EDP-938)?

Zelicapavir (EDP-938) is an antiviral treatment being studied for its effectiveness against RSV.

What age group was involved in the clinical trial?

The trial involved children aged 28 days to 36 months.

What type of study was conducted for Zelicapavir?

The study was a randomized, double-blind, placebo-controlled clinical trial.

What were the results of the clinical trial?

The trial showed that Zelicapavir is associated with a shortened duration of RSV symptoms.

ShareAdd on Google
Tags: ENTA Viatris Investor Conferences Healthcare Zelicapavir EDP-938 RSV clinical trial children
Last updated: Oct 20, 2025

Biotech snapshot

Cash runway
$211M liquidity · $3M/mo burn
~63 mo
Minimal dilution risk
Lead asset
EDP-235Phase 2
COVID-19 →